Skip to main content
. 2014 Dec 30;9(1):488–495. doi: 10.1021/nn505660r

Figure 5.

Figure 5

(A) PET ROI analysis of U87MG tumor uptake of 64CuCl2, GSH-[64Cu]CIS/ZnS and PEGylated GSH-[64Cu]CIS/ZnS RQDs over time (3 mice each group). (B) Biodistribution of 64CuCl2, GSH-[64Cu]CIS/ZnS and PEGylated GSH-[64Cu]CIS/ZnS RQDs in mice bearing U87MG tumors at 48 h postinjection. (3 mice each group).